Anzeige
Mehr »
Donnerstag, 23.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9YT | ISIN: ES0169501022 | Ticker-Symbol: PMRA
Tradegate
23.10.25 | 14:55
76,00 Euro
+0,33 % +0,25
1-Jahres-Chart
PHARMA MAR SA Chart 1 Jahr
5-Tage-Chart
PHARMA MAR SA 5-Tage-Chart
RealtimeGeldBriefZeit
76,4576,5516:51
76,4576,5516:51

Aktuelle News zur PHARMAMAR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.10.Pharmamar receives $50 million from Jazz Pharma for approval of Zepzelca + Tecentriq combo treatment for small cell lung cancer4
PHARMAMAR Aktie jetzt für 0€ handeln
15.10.PHARMA MAR, S.A.: The Company receives US$50 million milestone payment from Jazz Pharmaceuticals for the FDA's approval of Zepzelca® (lurbinectedin).9
03.10.FDA approves Zepzelca (Pharma Mar) + Tecentriq (Roche) combination therapy for treating lung cancer14
03.10.PHARMA MAR, S.A.: The Company reports details of the operations of the Liquidity Agreement between July 1, 2025 and September 30, 2025.2
17.09.PHARMA MAR, S.A.: Registration within the Madrid Mercantile Registry of the resolution to reduce capital by means of the redemption of own shares.4
30.07.PHARMA MAR, S.A.: The Company sends press release regarding first half 2025 results and announces a conference call with analysts and investors.7
30.07.PHARMA MAR, S.A.: Implementation of the reduction of share capital by means of the redemption of own shares approved by the General Shareholders' Meeting of 18 June 2025 under item number seven of the agenda.10
04.07.PHARMA MAR, S.A.: The Company reports details of the operations of the Liquidity Agreement between 23 and 30 June 2025.15
04.07.PharmaMar Geschäftsjahr 2024: Umsatz steigt um 11%, Nettogewinn schnellt7
04.07.PharmaMar FY 2024 slides: Revenue up 11%, net profit soars amid clinical advances4
02.07.PHARMA MAR, S.A.: The company reports the re-election of Mr. Eduardo Serra Rexach as member and secretary of the Appointments and Compensation and Sustainability Committee.4
24.06.XFRA CAPITAL ADJUSTMENT INFORMATION - 24.06.2025508Das Instrument GI8 CA39032G1046 GREAT EAGLE GOLD CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 24.06.2025 und ex Kapitalmassnahme am 25.06.2025 The instrument GI8 CA39032G1046 GREAT EAGLE GOLD...
► Artikel lesen
20.06.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 16 and 19 June 2025. Ending of the Share Buy-back Program and resumption of the liquidity agreement.2
18.06.PHARMA MAR, S.A.: It is reported that all proposed resolutions submitted by the Board to the General Shareholders' Meeting have been approved.2
18.06.PHARMA MAR, S.A.: The Company informs about the dividend payment charged to unrestricted reserves.2
18.06.PHARMA MAR, S.A.: Attached is a copy of the presentation to shareholders to be made at the General Shareholders' Meeting of Pharma Mar by the Chairman and by the Chief Financial Officer of the Company.1
16.06.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 9 June and 13 June 2025.2
10.06.PHARMA MAR, S.A.: Pharma Mar announces that the FDA grants Priority Review for Zepzelca® (lurbinectedin) and atezolizumab (Tecentriq®) combination in Extensive Stage Small Cell Lung Cancer.11
09.06.PHARMA MAR, S.A.: The company reports the transactions performed in the context of the Share Buy-back Program between 2 June and 6 June 2025.3
03.06.PharmaMar präsentiert auf der ASCO dass Zepzelca® (lurbinectedin) in Kombination mit Atezolizumab (Tecentriq®) das Überleben als Erstlinien-Erhaltungstherapie bei kleinzelligem Lungenkrebs786Madrid (ots/PRNewswire) - - Die Erstlinien-Erhaltungskombinationstherapie verringerte das Risiko eines Fortschreitens der Krankheit oder des Todes um 46%, mit einer medianen Gesamtüberlebenszeit von...
► Artikel lesen
Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1